Verona is extending Ohtuvayre's life cycle through new formulations and fixed-dose combinations, aiming for cash flow ...

For further information please contact: Verona P Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique ...

Ohtuvayre is due to launch in the US in the third quarter of this year, assisted by a $650 million debt facility that Verona agreed a few months ago to build its commercial capabilities.

and now Verona has revealed the drug made approximately $36 million in the final three months of 2024, off more than 16,000 prescriptions. Chief executive David Zaccardelli said Ohtuvayre was off ...

Verona Pharma (VRNA ... Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and ...

Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

At close: 3 April at 16:00:02 GMT-4 ...